BACKGROUND: We reviewed the effectiveness and safety of cardiac resynchronization therapy (CRT) for patients with New York Heart Association (NYHA) class IV non-ambulatory heart failure (NAHF). METHODS: From 2006 to 2011, 310 patients underwent CRT at Kobe University Hospital and Himeji Cardiovascular Center because of heart failure. Of these, 29 NAHF patients were retrospectively analyzed. The control group comprised 21 age- and ejection fraction-matched patients with NAHF who did not undergo CRT from the ICU database of Kobe University Hospital. The primary endpoint was all-cause death and hospitalization for heart failure. Response was defined as a >15% reduction in left ventricular end-systolic volume (LVESV). RESULTS: CRT was performed successfully without serious complications in all patients. Twenty-three patients (79%) were discharged 19±15 days after CRT implantation, while 6 (21%) died during their hospital stay due to progressive heart failure. Compared with the control group, patients in the CRT group showed significant improvements in the primary endpoint (log-rank p=0.04). Six patients (21%) were defined as responders and the Kaplan-Meier curve showed that responders experienced a better outcome than non-responders (log-rank p=0.029). LV dyssynchrony before implantation was significantly related to the occurrence of the primary endpoint (p=0.02). CONCLUSIONS: CRT can be safely used in patients with NAHF and can improve long-term patient outcomes, especially in treatment responders.
BACKGROUND: We reviewed the effectiveness and safety of cardiac resynchronization therapy (CRT) for patients with New York Heart Association (NYHA) class IV non-ambulatory heart failure (NAHF). METHODS: From 2006 to 2011, 310 patients underwent CRT at Kobe University Hospital and Himeji Cardiovascular Center because of heart failure. Of these, 29 NAHFpatients were retrospectively analyzed. The control group comprised 21 age- and ejection fraction-matched patients with NAHF who did not undergo CRT from the ICU database of Kobe University Hospital. The primary endpoint was all-cause death and hospitalization for heart failure. Response was defined as a >15% reduction in left ventricular end-systolic volume (LVESV). RESULTS: CRT was performed successfully without serious complications in all patients. Twenty-three patients (79%) were discharged 19±15 days after CRT implantation, while 6 (21%) died during their hospital stay due to progressive heart failure. Compared with the control group, patients in the CRT group showed significant improvements in the primary endpoint (log-rank p=0.04). Six patients (21%) were defined as responders and the Kaplan-Meier curve showed that responders experienced a better outcome than non-responders (log-rank p=0.029). LV dyssynchrony before implantation was significantly related to the occurrence of the primary endpoint (p=0.02). CONCLUSIONS: CRT can be safely used in patients with NAHF and can improve long-term patient outcomes, especially in treatment responders.
Authors: Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: F Zannad; S Briancon; Y Juilliere; P M Mertes; J P Villemot; F Alla; J M Virion Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: Peter J Cowburn; Harshna Patel; Robynn E Jolliffe; Robert W Wald; John D Parker Journal: Eur J Heart Fail Date: 2005-03-02 Impact factor: 15.534
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Lynne Warner Stevenson; Leslie W Miller; Patrice Desvigne-Nickens; Deborah D Ascheim; Michael K Parides; Dale G Renlund; Ronald M Oren; Steven K Krueger; Maria Rosa Costanzo; L Samuel Wann; Ronald G Levitan; Donna Mancini Journal: Circulation Date: 2004-08-16 Impact factor: 29.690
Authors: Bengt Herweg; Arzu Ilercil; Ray Cutro; Robert Dewhurst; Sendhil Krishnan; Mark Weston; S Serge Barold Journal: Am J Cardiol Date: 2007-05-15 Impact factor: 2.778